Synagis

Active Ingredient(s): Palivizumab
FDA Approved: * June 19, 1998
Pharm Company: * MEDIMMUNE
Category: Vaccination

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Synagis Overview

Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections.[4][3] It is recommended for infants at high-risk for RSV due to conditions such as prematurity or other medical problems including heart or lung diseases.[4][3] The most common side effects include fever and rash.[4]&a...

Read more Synagis Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Palivizumab

Recent Synagis Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Palivizumab
  • Injection: 100mg, 100mg/ml, 50mg, 50mg/ml
  • Vial: 100mg/vial, 50mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Synagis: (4 results)

Sorted by National Drug Code
  • 60574-4113 Synagis 100 mg/ml Intramuscular Injection, Solution by Medimmune, LLC
  • 60574-4114 Synagis 50 mg/.5ml Intramuscular Injection, Solution by Medimmune, LLC
  • 66658-230 Synagis 50 mg/.5ml Intramuscular Injection, Solution by Swedish Orphan Biovitrum Ab (Publ)
  • 66658-231 Synagis 100 mg/ml Intramuscular Injection, Solution by Swedish Orphan Biovitrum Ab (Publ)

Other drugs which contain Palivizumab or a similar ingredient: (1 result)

Related Synagis Topics:

synagis
side effects long term...